Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.…
PharmAla Biotech Signs Supply and Data Agreement with Aalborg University Hospital for Danish Randomized Trial of MDMA-Assisted Treatment for Service-Related PTSD
Pharmala Biotech Holdings (CNSX: MDMA) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.1400 CAD on 20 November 2026, up 27.3% over 52 weeks. Its 52-week range is 0.0850 CAD to 0.3300 CAD: the price is 57.6% below the high and 64.7% above the low.
Its market capitalisation is 15.43M CAD.
Pharmala Biotech Holdings reports return on equity of -88.5%, an operating margin of -112.1% and revenue up 279.7% year over year.
It holds more cash than debt, a net cash position of 249.14K CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.